Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone

British Journal of Cancer

Volumn 75, Issue 11, 1997, Pages 1585-1592

  Jungwirth, A ^a,c   Schally, A V ^a,b   Pinski, J ^a   Halmos, G ^a   Groot, K ^a   Armatis, P ^a   Vadillo Buenfil, M ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c St Johanns Spital   (Austria)

Author keywords

DU 145; Dunning tumour; Growth hormone releasing hormone antagonist; Insulin like growth factor; PC 3; Prostate cancer

Indexed keywords

ANDROGEN; ANTINEOPLASTIC AGENT; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; MZ 4 71; SOMATOMEDIN B; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONE BLOOD LEVEL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MEMBRANE BINDING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; RAT; TUMOR GROWTH; TUMOR VOLUME;

EID: 0030979558     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.271     Document Type: Article

References (38)

1. Angelloz-Nicoud P and Binoux M (1945) Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and (IGF) binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 136: 5485-5492
2. Breier BH, Gallaher BW and Gluckman PD (1991) Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. J Endocrinol 128: 347-357
3. Cohen P, Peehl DM and Rosenfeld RG (1994) The IGF axis in the prostate. Horm Metab Res 26: 81-84
4. Crawford BA, Martin JI, Howe CJ, Handelsman DJ and Baxter RC (1992) Comparison of extraction methods for insulin-like growth factor-I in rat serum. J Endocrinol 134: 169-176
5. Daughaday WH, Mariz IK and Blethen SL (1980) Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol extracted serum. J Clin Endocrinol Metab 51: 781-788
6. Davies P and Eaton CL (1991) Regulation of prostate growth. J Endocrinol 131: 5-17
7. D'Ercole AJ, Stiles AD and Underwood LE (1984) Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA 81: 935-939
8. Eisenberger MA, Reyno LM, Jodrell DI, Sinibaldi VJ, Tkaczuk KH, Sridhara R, Zuhowski EG, Lowiti MH, Jacobs SC and Egorin MJ (1993) Suramin. an active drug for prostate cancer: interim observations in a phase I trial. J Natl Cancer Inst 85: 611-621
9. Figueroa JA, Lee AV, Jackson JG and Yee D (1995) Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop. J Clin Endocrinol Metab 80: 3476-3482
10. Froesch ER, Schmid C, Schwander J and Zapf J (1985) Actions of insulin-like growth factors. Annu Rev Physiol 47: 443-467
11. Garnick MB (1993) Prostate cancer: screening, diagnosis, and management. Ann Int Med 118: 804-818
12. Isaacs JT, Heston WD, Weissman R and Coffey DS (1978) Animal models for the hormone-sensitive and -insensitive prostatic adenocarcinomas. Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res 38: 4353-4359
13. Iwamura M, Sluss PM, Casamento JB and Cockett ATK (1993) Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22: 243-252
14. Janik P, Briand P and Hartmann NR (1975) The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 35: 3698-370
15. Kaighn ME, Shankar Narayan K, Ohnuki Y, Lechner JF and Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23
16. Kováes M, Zarándi M, Halmos G, Groot K and Schally AV (1996) Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action. Endocrinology 137: 5364-5369
17. Lee PDK, Baker BK, Liu F, Kwan EYW and Hintz RL (1996) A homologous radioimmunoassay for rat insulin-like growth factor (IGF-I). Implications for studies of human IGF-I physiology. J Clin Endocrinol Metab 81: 2002-2005
18. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ and Wennberg JE (1996) Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 88: 166-173
19. Macaulay VM (1992) Insulin-like growth factors and cancer. Br J Cancer 65: 311-320
20. Munson JP and Rodbard D (1980) A versatile computerized approach for characterization of ligand binding systems. Anal Biochem 107: 220-239
21. Parker SL, Tong T, Bolden S and Wingo PA (1996) Cancer statistics. 1996. CA Cancer J Clin 65: 5-27
22. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D and Baserga R (1993) Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor I. Cancer Res 53: 1102-1106
23. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M and Armatis P (1995) Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst 87: 1787-1794
24. Pinski J, Schally AV, Halmos G, Szepeshazi K and Groot K (1994) Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res 54: 5895-5901
25. Pinski J, Schally AV, Jungwirth A, Groot K, Halmos G, Armatis P, Zarandi M and Vadillo-Buenfil M (1996) Inhibition of growth of human small-cell and non-small-cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH). Int J Oncol 9: 1099-1105
26. Plumb JA, Milroy R and Kaye SB (1989) Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5,-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 49: 4435-4440
27. Pollak M and Richard M (1990) Suramin blockade of insulin-like growth factor I-stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 82: 1349-1352
28. Reiter E, Kecha O, Hennuy B, Lardinois S, Klug M, Bruyninx M, Closset J and Hennen G (1995) Growth hormone directly affects the function of the different lobes of the rat prostate. Endocrinology 136: 3338-3345
29. Reubi JC, Waser B, Schaer JC and Markwalder R (1995) Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metabol 80: 2806-2814
30. Schally AV, Comaru-Schally AM and Gonzales-Barcena D (1990) Present status of agonistic and antagonistic analogs of LH-RH in the treatment of advanced prostate cancer. Biomed Pharmacother 46: 465-471
31. Sharifi R, Soloway M and the Leuprolide Study Group (1990) Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 143: 68-71
32. Sinowatz F, Breipohl W, Waters MI, Lincoln D, Lobie PE and Amselgruber W (1991) Growth hormone receptor expression in the Dunning R 3327 prostatic carcinoma of the rat. Prostate 19: 273-278
33. Steel RGD and Torrie J (1976) Principles and Procedures of Statistics. p. 114. McGraw-Hill: New York
34. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer 21: 274-281
35. Tanaka H, Asami O, Hayano T, Sasaki I, Yoshitake Y and Nishikawa K (1989) Identification of a family of insulin-like growth factor II secreted by cultured rat epithelial-like cell line 18,54-SF: application of a monoclonal antibody. Endocrinology 124: 870-877
36. Walsh PC, Partin AW and Epstein JI (1994) Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152: 1831-1836
37. Watson SA, Durrant L and Morris DL (1988) Growth promoting action of gastrin on human colonic and gastric tumor cell cultures in vitro. Br J Surg 75: 342-345
38. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K and Schally AV (1994) Synthesis and biological activities of highly potent antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci USA 91: 12298-12302